Table 1 Distribution of prevalence of vaccine and non-vaccine serotypes listed in order of prevalence among infants
| Â | Infants | Mothers | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
non-vaccine serotypes: | Infant's age (months) | |||||||||
| Â | 0 | 2 | 5 | 12 | ever* | 0 | 2 | 5 | 12 | ever* |
18B | Â | Â | Â | Â | 0.0% | 0.5% | Â | Â | Â | 0.5% |
39 | Â | Â | Â | Â | 0.0% | 0.5% | Â | Â | Â | 0.5% |
48 | Â | Â | Â | Â | 0.0% | Â | Â | 0.5% | Â | 0.5% |
18A | Â | Â | Â | Â | 0.0% | Â | Â | 0.5% | 0.5% | 1.0% |
35F | Â | Â | Â | Â | 0.0% | Â | Â | 0.5% | 0.5% | 1.0% |
35C | Â | Â | 0.5% | Â | 0.5% | Â | Â | Â | Â | 0.0% |
47 | Â | 0.5% | Â | Â | 0.5% | Â | Â | Â | Â | 0.0% |
24 | Â | Â | 0.5% | Â | 0.5% | 0.5% | Â | Â | Â | 0.5% |
9N | Â | Â | Â | 0.5% | 0.5% | Â | Â | Â | 0.5% | 0.5% |
19C | Â | Â | Â | 0.5% | 0.5% | Â | 0.5% | 0.5% | Â | 1.0% |
20 | Â | 1.0% | 0.5% | Â | 1.0% | Â | Â | Â | 0.5% | 0.5% |
2 | Â | 0.5% | Â | 0.5% | 1.0% | Â | 0.5% | 0.5% | 0.5% | 1.5% |
23A | Â | 1.0% | 0.5% | Â | 1.5% | Â | 0.5% | Â | Â | 0.5% |
31 | Â | 1.0% | 0.5% | Â | 1.5% | Â | Â | Â | 0.5% | 0.5% |
16 | Â | 1.0% | 1.0% | 0.5% | 2.0% | Â | Â | Â | 0.5% | 0.5% |
38 | Â | Â | 0.5% | 1.5% | 2.0% | Â | 0.5% | 0.5% | Â | 1.0% |
17 | Â | 0.5% | 1.5% | Â | 2.0% | Â | 1.0% | 0.5% | 1.0% | 2.0% |
28 | Â | 1.5% | 1.0% | Â | 2.0% | Â | 1.0% | 1.0% | Â | 2.0% |
22 | Â | 2.0% | 0.5% | Â | 2.6% | Â | Â | 0.5% | 0.5% | 1.0% |
9L | Â | 0.5% | 1.5% | 1.0% | 2.6% | 0.5% | Â | 0.5% | Â | 1.0% |
23B | Â | 1.5% | 1.5% | 0.5% | 3.1% | 1.0% | 1.0% | 1.0% | 1.0% | 3.6% |
33 | Â | 2.0% | 2.0% | Â | 3.6% | Â | 1.0% | Â | Â | 1.0% |
10 | Â | 3.1% | 1.5% | Â | 3.6% | 1.0% | 1.0% | 0.5% | Â | 2.0% |
12 | Â | 2.6% | 2.0% | Â | 4.1% | Â | Â | Â | Â | 0.0% |
7C | Â | 3.1% | 3.1% | Â | 4.1% | Â | 1.0% | 0.5% | Â | 1.5% |
19B | Â | 1.5% | 2.6% | 1.5% | 4.6% | 0.5% | 1.0% | 0.5% | 0.5% | 2.6% |
9A | Â | Â | 4.6% | 1.0% | 5.6% | Â | Â | 1.0% | Â | 1.0% |
13 | Â | 2.0% | 1.0% | 2.6% | 5.6% | Â | 1.0% | Â | 0.5% | 1.5% |
21 | Â | 2.6% | 2.6% | 1.0% | 5.6% | 1.5% | Â | 0.5% | Â | 2.0% |
11 | Â | 2.6% | 2.0% | 2.0% | 6.1% | 1.5% | 1.0% | 0.5% | Â | 3.1% |
35B | Â | 2.6% | 2.6% | 2.0% | 6.1% | Â | 1.0% | 0.5% | 2.0% | 3.1% |
34 | 0.5% | 4.6% | 0.5% | 1.0% | 6.1% | 2.6% | 1.5% | 1.5% | Â | 5.1% |
15 | Â | 7.1% | 6.1% | 6.1% | 15.3% | Â | 2.0% | 0.5% | 1.0% | 3.6% |
any non-vacc | 0.5% | 43.4% | 41.3% | 23.0% | 73.0% | 10.2% | 16.8% | 13.3% | 9.7% | 38.8% |
13-PCV serotypes : | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
7F | Â | Â | 0.5% | Â | 0.5% | Â | Â | 0.5% | Â | 0.5% |
1 | Â | Â | 0.5% | 0.5% | 1.0% | Â | Â | Â | Â | 0.0% |
5 | Â | Â | 1.0% | Â | 1.0% | Â | Â | Â | Â | 0.0% |
18C †|  | 1.0% |  | 0.5% | 1.5% |  | 1.0% |  | 1.0% | 2.0% |
3 | Â | 1.0% | 1.0% | 0.5% | 2.6% | Â | 0.5% | 0.5% | 0.5% | 1.5% |
9V †|  | 0.5% |  | 3.1% | 3.6% |  | 0.5% |  | 1.0% | 1.5% |
4 †|  | 2.6% | 1.0% | 1.0% | 4.6% | 0.5% | 0.5% |  | 0.5% | 1.5% |
19A | Â | 1.5% | 5.6% | 5.6% | 11.2% | 0.5% | 0.5% | 2.6% | 0.5% | 3.6% |
23F †|  | 8.2% | 7.1% | 6.6% | 17.3% | 0.5% | 0.5% | 1.0% | 2.6% | 4.6% |
14 †|  | 4.1% | 7.7% | 11.2% | 20.9% | 0.5% | 2.0% | 1.0% | 1.5% | 4.1% |
6B †|  | 8.7% | 15.3% | 12.2% | 26.5% | 1.0% | 0.5% | 2.0% | 1.0% | 4.6% |
6A | Â | 6.6% | 12.8% | 12.8% | 27.0% | Â | 0.5% | 2.0% | 2.6% | 5.1% |
19F †| 1.0% | 7.1% | 8.2% | 15.8% | 27.6% | 0.5% | 0.5% | 2.0% | 1.0% | 4.1% |
any vacc | 1.0% | 39.3% | 58.2% | 63.3% | 89.3% | 3.1% | 7.7% | 11.2% | 12.2% | 28.6% |
any serotype | 1.5% | 78.1% | 87.8% | 78.6% | 98.0% | 13.3% | 24.5% | 23.5% | 21.4% | 55.1% |